Holen Sie sich die Stockscreener-App
41.46
2.23%
-0.945
Schlusskurs vom Vortag:
$42.41
Offen:
$42.32
24-Stunden-Volumen:
504.64K
Relative Volume:
1.01
Marktkapitalisierung:
$2.06B
Einnahmen:
$499.95M
Nettoeinkommen (Verlust:
$-36.36M
KGV:
-53.84
EPS:
-0.77
Netto-Cashflow:
$24.22M
1W Leistung:
+5.58%
1M Leistung:
+4.38%
6M Leistung:
+29.89%
1J Leistung:
+23.17%
1-Tages-Spanne:
$41.13
$42.70
1-Wochen-Bereich:
$39.20
$43.18
52-Wochen-Spanne:
$28.29
$43.18
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Vergleichen Sie ATRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
41.46 | 2.11B | 499.95M | -36.36M | 24.22M | -0.77 |
|
ISRG
Intuitive Surgical Inc
|
586.24 | 207.41B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
202.75 | 58.46B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.13 | 39.60B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
252.47 | 36.63B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
40.52 | 32.47B | 27.43B | 1.27B | 1.01B | 1.5829 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
AtriCure, Inc. (ATRC) soars to 52-week high, time to cash out? - MSN
(ATRC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
AtriCure, Inc. (ATRC) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Is AtriCure Inc. stock a defensive play in 2025July 2025 Movers & Fast Gaining Stock Strategy Reports - ulpravda.ru
Will AtriCure Inc. stock benefit from green energy trendsMarket Weekly Review & Daily Price Action Insights - ulpravda.ru
Will AtriCure Inc. stock benefit from automationJuly 2025 Short Interest & High Return Trade Guides - ulpravda.ru
Will AtriCure Inc. stock continue upward momentumQuarterly Risk Review & AI Powered Trade Plan Recommendations - ulpravda.ru
Will AtriCure Inc. stock attract ESG investorsJuly 2025 Breakouts & High Accuracy Trade Alerts - ulpravda.ru
AtriCure stock hits 52-week high at $43.18 By Investing.com - Investing.com Canada
Fed Watch: How risky is AtriCure Inc. stock nowJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
Is AtriCure Inc. stock trading at a premium valuation2025 Earnings Impact & Community Trade Idea Sharing Platform - ulpravda.ru
AtriCure (NASDAQ:ATRC) Share Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
AtriCure, Inc. (NASDAQ:ATRC) Nasdaq Index Fund Medical Devices - Kalkine Media
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriCl - PharmiWeb.com
AtriCure Inc (ATRC) Product Pipeline Analysis Report 2025: Portfolio Led by Isolator Synergy, AtriClip, Hybrid AF Therapy, and cryoICE cryoSPHERE TechnologiesResearchAndMarkets.com - The AI Journal
Liquidity Mapping Around (ATRC) Price Events - Stock Traders Daily
AtriCure (ATRC): Assessing Valuation After First-In-Human PFA/RFA Procedures and Renewed Analyst Optimism - Yahoo Finance
Assessing AtriCure’s Valuation After a 33.4% Rally in 2025 - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Has AtriCure (ATRC) Outpaced Other Medical Stocks This Year? - sharewise.com
AtriCure (NASDAQ:ATRC) Stock Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
What AtriCure (ATRC)'s First Dual-Energy PFA–RFA Procedures Mean For Shareholders - Sahm
Big Money Moves: Will AtriCure Inc stock benefit from green energy trendsVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Analysts See an Over 26% Upside in AtriCure (ATRC) - Insider Monkey
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Assessing AtriCure (ATRC) Valuation After Milestone First‑in‑Human Results for Its Dual Energy Ablation Platform - Sahm
AtriCure price target raised to $48 from $42 at JPMorgan - MSN
AtriCure announces first patients treated with dual energy platform - MSN
Quarterly Recap: What valuation multiples suggest for AtriCure Inc stock - moha.gov.vn
Is AtriCure Inc. stock a buy in volatile marketsShare Buyback & Smart Allocation Stock Tips - Улправда
AtriCure (ATRC) Is Up 6.32% in One Week: What You Should Know - Yahoo Finance
Why AtriCure Inc. stock is favored by top institutionsQuarterly Earnings Summary & Safe Investment Capital Preservation Plans - DonanımHaber
Canaccord Genuity Reaffirms Their Buy Rating on Atricure (ATRC) - The Globe and Mail
Atrial Fibrillation Market | Global Market Analysis Report2036 - Fact.MR
Understanding the Setup: (ATRC) and Scalable Risk - Stock Traders Daily
How supply chain issues affect AtriCure Inc. stockJuly 2025 Spike Watch & Safe Capital Preservation Plans - Улправда
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference - BioSpace
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way? - 富途牛牛
AtriCure Earnings Notes - Trefis
JP Morgan Raises AtriCure (ATRC) Price Target to $48 | ATRC Stoc - GuruFocus
ATRC FinancialsIncome Statement - Quiver Quantitative
JPMorgan Chase & Co. Boosts AtriCure (NASDAQ:ATRC) Price Target to $48.00 - MarketBeat
AtriCure, Inc. $ATRC Shares Acquired by Squarepoint Ops LLC - MarketBeat
AtriCure (ATRC) Is Up 6.3% After First Dual-Energy PFA–RFA Human Procedures Success - Sahm
AtriCure (ATRC) Is Up 6.3% After Dual Energy PFA–RFA First-in-Human SuccessHas The Bull Case Changed? - Yahoo Finance
Loss Report: What valuation multiples suggest for AtriCure Inc stockJuly 2025 Outlook & Fast Entry Momentum Alerts - moha.gov.vn
AtriCure treats first patients with dual PFA/RF system - MedTech Dive
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atricure Inc-Aktie (ATRC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEHRWEIN SVEN | Director |
Nov 25 '25 |
Option Exercise |
19.95 |
4,967 |
99,092 |
39,341 |
| WEHRWEIN SVEN | Director |
Nov 25 '25 |
Sale |
38.00 |
4,967 |
188,746 |
34,374 |
| WEHRWEIN SVEN | Director |
Nov 24 '25 |
Sale |
37.32 |
5,033 |
187,832 |
34,374 |
| Noznesky Justin J | Chief Mktg & Strategy Officer |
Nov 26 '25 |
Sale |
37.29 |
5,166 |
192,640 |
78,798 |
1.30%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):